Background-Women are at a higher risk for bleeding/vascular complications (VC) related to cardiovascular procedures.
B leeding and vascular complications (VC) related to invasive cardiovascular procedures are associated with significant morbidity and mortality. [1] [2] [3] [4] [5] Observational studies demonstrate that female gender is a powerful predictor of bleeding/VC in patients undergoing both diagnostic catheterization and percutaneous coronary intervention (PCI) [5] [6] [7] [8] [9] [10] [11] [12] by means of the femoral approach. Over the last decade, several procedural-related improvements, such as use of smaller sheaths, successful use of vascular closure devices (VCD), 3, 11, 13, 14 better access techniques, 15 and improved antithrombotic therapies, 16 have led to an overall decline in complication rates. 14, 17, 18 
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Gender differences in VC rates may be due to an increased prevalence of comorbid conditions, such as older age, diabe-tes, peripheral arterial disease, and smaller vessel size in women. 7, 19 However, women remain at higher risk for bleeding and VC even after accounting for these differences. 6 Although improvements in technique and pharmacology have led to a decrease in bleeding/VC rates over the past decade, it is unknown whether this has led to improved rates of bleeding/VC, specifically among women, and whether there has been a narrowing of the gender gap.
Therefore, we examined a large multicenter, regional PCI registry to assess recent temporal trends in overall bleeding/VC from 2002 to 2007 in men and women. Although previous studies have focused on the independent risk of VC conferred by female gender, we sought to further determine whether there were modifiable risk factors for bleeding and VC, particularly to women undergoing PCI. In addition, we sought to determine whether women remain at significantly higher risk than men for VC during the entire study period, even after accounting for differences in baseline clinical variables.
Methods
Data were obtained from the PCI registry of the Northern New England Cardiovascular Disease Study Group (NNE). 6 The NNE is a voluntary research consortium composed of clinicians, research scientists, and hospital administrators at 10 institutions in NNE that perform coronary revascularization. The intent of the group is to foster continuous improvement in the quality of care for patients with cardiovascular disease in NNE through pooling of process and outcome data, with timely feedback of data to clinicians.
Detailed data on demographics, medical history, coronary anatomy and function, procedural indications, and process, including PCI pharmacotherapy and the use of closure devices, and in-hospital outcomes were collected using a standardized reporting form. All data were verified by chart review until hospital discharge by a dedicated quality assurance nurse. Consistent with national trends, 20 Ͼ95% of the procedures were performed from the femoral approach. Use and type of anticoagulation prior, during, and post-PCI were left to the discretion of the operator. For patients who received thrombolytics, rescue, facilitated, and delayed invasive PCI approaches were used according to the clinical situation and operator discretion.
The definitions applied in this analysis were consistent throughout the study period. Bleeding/VC was defined as any access site-related bleeding requiring a transfusion or an access site complication requiring surgical or procedural intervention, such as access artery dissection, perforation, arteriovenous fistula, pseudoaneurysm, or embolism, during the index hospitalization. Major adverse cardiac event included myocardial infarction (MI), stroke, or death during the index hospitalization. Stroke was defined as a clinical neurological deficit from an ischemic or hemorrhagic neurological insult post-PCI that did not resolve completely within 24 hours of the procedure. MI was defined as symptoms of suggestive of ischemia (chest pain and shortness of breath), dynamic EKG changes, or new Q waves in the setting of any elevation of both creatine phosphokinase and creatine phosphokinase-MB Ͼ1ϫ normal level. Death was defined as death from any cause during the index hospitalization. The number of procedures and death was independently validated with the use of administrative data.
Statistical Analysis
Univariate comparisons were done using the Mantel-Haenszel 2 test for categorical variables and 2-sample t tests for continuous variables. Multiple logistic regression was used to analyze patients and procedural risk factors and to develop a predictive model. Variables were selected for the model based on statistical significance (PϽ0.10) and clinical relevance. The influence of 2 pharmacological agents-bivalirudin and glycoprotein receptor inhibitors-were examined in the model while controlling for other independent clinical and procedural predictors. The model containing all the candidate variables was reduced using significance testing and likelihood ratio testing to find a parsimonious model. 6 The model was developed for women alone, and then compared with predictors found in analyzing VC occurring in men alone. The Hosmer-Lemeshow goodness-of-fit C statistic was calculated for the models.
Two logistic regression models were developed to determine whether bleeding/VC were associated with increased risk of major adverse cardiovascular events. The first model incorporated all clinical variables that differed on univariate analysis (PϽ0.10) between patients with and without bleeding/VC; the second model incorporated both clinical and procedural variables that varied between patients with and without bleeding/VC. Temporal trends in bleeding/VC were evaluated over time and for men and women, using crude data. To compare men and women, adjusted odds ratios (ORs) were calculated using the risk predictors identified in logistic modeling for VC in men and women for each year of the study period.
Results
From 2002 to 2007, a total of 46 830 consecutive patients undergoing PCI in NNE were enrolled in the registry, including 13 653 women (29.2%) and 33 177 men (70.8%). Baseline clinical and procedural variables in women with or without bleeding/VC are shown in Table 1 . Similarly, baseline clinical and procedural variables in men with and without bleeding/VC are shown in Table 2 . Women with bleeding/VC were likely to be older, have renal failure, congestive heart failure, and had a lower body mass index. They were less likely to have a history of dyslipidemia, prior revascularization, or be current smokers. Men with bleeding/VC had a generally similar clinical, procedural, and pharmacological risk profile. The relationship between risk of bleeding/VC and increasing age among women was linear ( Figure 1 ). Similarly, there was no U-or J-shaped curve in the inverse relationship demonstrated between increasing body mass index and bleeding/VC rates ( Figure 2 ).
For the entire study period, the overall rate of bleeding/VC was higher in women in comparison with men (4.5Ϯ1.3% versus 1.6Ϯ0.5%; PϽ0.004). Temporal trends from 2002 to 2007 showed a significant 50% decline in the incidence of complications in both women and men ( Figure 3 ). Bleeding/VC rates decreased steadily each year of the study and changed from 6.0% to 2.9% in women and 2.1% to 0.97% in men, from 2002 to 2007. However, the adjusted OR for female gender predicting bleeding/VC did not change over time: 2.63 (2.02 to 3.45) in 2002 and 2.61 (1.73 to 3.91) in 2007.
Independent clinical and procedural predictors of bleeding/VC in women included older age, renal failure, presen- tation with non-ST-elevation MI or cardiogenic shock, and the use of larger sheaths (Table 3) . Predictors associated with a decreased risk included dyslipidemia, use of closure devices, and a prior history of revascularization. The C statistic for this model was 0.65. The addition of bivalirudin and glycoprotein receptor inhibitor to this model demonstrated a 52% reduction in bleeding/VC for women treated with bivalirudin during PCI (PϽ0.001). VCD utilization was further examined by evaluating women who underwent closure versus those who did not (Table 4 ). Particular high-risk variables were more prevalent among women who received a closure device (advanced age, thrombolytics, and ST-elevation MI presentation), whereas other high-risk variables were more common among patients who did not (prior history of peripheral arterial disease, presentation in cardiogenic shock). VCD utilization increased significantly over the time of the study (16.6% versus 62.2%, Pϭ0.0001). After controlling for clinical differences in a logistic regression model, closure device utilization was associated with a 25% reduction in bleeding/VC for both men and women (Tables 3 and 5) .
Clinical outcomes during index hospitalization are shown in Table 6 . Women with bleeding/VC had a nearly 3-fold increased incidence of stroke, MI, and all-cause death compared with women without bleeding/VC. On logistic regression analysis, after controlling for clinical differences, bleeding/VC were a strong independent predictor of major adverse cardiac event (OR, 1.84; 95% CI, 1.31 to 2.62; Pϭ0.001), and after controlling for both clinical and procedural differences, women with bleeding/VC had a 75% increased risk of death, myocardial infraction, or stroke during their index hospitalization (OR, 1.75; 95%, CI 1.23 to 2.51).
Discussion
Over the past 2 decades, trials and observational studies have demonstrated a higher rate of bleeding/VC in women undergoing invasive cardiovascular procedures compared with men. 7, 8, 10, 11 Our findings from a large, multicenter, regional PCI registry demonstrate significantly improved rates of bleeding/VC in women undergoing PCI during the past 6 years. The incidence of bleeding/VC decreased Ͼ50% in both men and women during the study period. Although these results are encouraging, our study also demonstrates that women continue to be more than twice as likely as men to have significant bleeding/VC after PCI.
Our data are consistent with recent reports, which have shown decreasing overall rates of VC after PCI. 3, 14, 17 The largest study to date, from the American College of Cardiology-National Cardiovascular Date Registry (ACC-NCDR) registry, evaluated 166 680 men and women undergoing diagnostic and interventional cardiac procedures from 1998 to 2001 and showed that female gender was a strong predictor of VC (relative risk, 2.18; PϽ0.001) and associated death (relative risk, 2.59; PϽ0.001) compared with men. 11 A follow-up study from the same authors evaluating data on 13 878 catheterization patients (5225 women) in 2003 revealed an improvement in VC rates in women but still demonstrated an adjusted relative risk of 1.40 compared with men. 12 The authors attributed the decline in risk to use of smaller sheaths and improved postprocedure sheath management. Applegate et al 21 reported a more recent experience from a large single-center patient cohort from 1998 to 2005. This study also demonstrated an overall decrease in bleeding/VC rates in women undergoing cardiac catheterization, but their study suggested that women in 2005 were no longer at any increased adjusted risk (OR, 0.98; 95% CI, 0.33 to 2.87) compared with men. 21 Our current analysis represents one of the largest multicenter PCI reports in women and spans an era of contemporary practice. In parallel, but separate analysis of men and women undergoing PCI, clinical and procedural variables, such as older age, renal insufficiency, cardiogenic shock, and large sheath sizes were significant independent predictors of bleeding/VC in both genders. These findings are consistent with previous analyses, suggesting an association between cardiogenic shock (which may be a surrogate for intra-aortic balloon placement), 22 renal failure 6 and larger sheaths, 11, 17 and bleeding/VC in studies including both men and women. Previous studies have been inconsistent regarding an independent relationship for older age and bleeding/VC. 11 Our study focusing only on PCI and not on diagnostic procedures, as well as a more contemporary practice, demonstrated an independent and strong risk of bleeding/VC among elderly women, suggesting that caution is especially warranted in this high-risk group.
A decreased risk of bleeding/VC in women was seen with clinical factors of dyslipidemia and previous coronary artery bypass grafting or PCI. The role of dyslipidemia (or its potential surrogate, statin therapy) is unknown and warrants further study. The protective value of previous revascularization may relate to the importance of known femoral anatomy. This finding is consistent with the concept of protection by means of enhanced care in vascular access and closure techniques, 15 including the use of fluoroscopy-guided access to define the "safety zone" for access. 23 In addition, VCD use was associated with a 25% decreased risk of bleeding/VC in both male and female patients. These findings should be interpreted with caution because data on closure device use can be confounded by selection bias and may be influenced by unmeasured patient characteristics. After controlling for known clinical, procedural, and treatment differences, use of closure device was associated with a significant reduction in complication rates. We also show that use of bivalirudin was associated with a significantly decreased risk of bleeding/VC among 13 653 contemporary women undergoing PCI. These findings are supported by a recent gender-specific analysis of the ACUITY trial, which demonstrates a significantly lower rate of bleeding, specifically in women receiving bivalirudin. 24 We also evaluated trends in the use of procedural variables during the study period and found a significant increase in the use of bivalirudin for PCI, fluoroscopy-guided access, and use of closure devices from 2002 to 2007. For example, bivalirudin utilization increased from 12.1% to 40.3% of women undergoing PCI during the 6-year study period (Pϭ0.0001). These changes parallel a decrease in the overall rate of bleeding/VC and suggest that implementation of changes in practice have made the procedure safer and, in part, account for the improved outcomes seen over time.
Bleeding/VC are associated with significant early morbidity and mortality. 1, 4, 5, 25 In our patient cohort, bleeding/VC were associated with a significantly higher risk of major cardiovascular adverse events (Table 6 ). On logistic regression analysis, in our female patient cohort, bleeding/VC were an independent predictor of major adverse cardiac event (OR, 1.84; 95% CI, 1.31 to 2.62; Pϭ0.001). Bleeding or need for surgical intervention related to a VC post-PCI can lead to cessation of antiplatelet therapy, need for blood product transfusion, significant anemia, and prolonged hospitalization, all of which amplify risk for an adverse cardiovascular event, such as MI, stroke, and death post-PCI. 3, 26 Our findings underscore the high morbidity and mortality of bleeding/VC in women and the need for careful management of patients at higher risk.
Finally, our analysis shows that despite an overall improvement in bleeding/VC in both men and women, there continues to be a persistent gender difference (Figure 3) . The adjusted OR for female gender predicting bleeding/VC remained unchanged during the study period with an Ϸ2.5-fold increase in risk for bleeding/VC in women compared with men. Independent predictors of bleeding/VC were similar in men and women (Tables 3 and 5) ; however, women continue to be at a higher inherent risk unaccounted for by traditional, measured baseline clinical, and procedural differences between the 2 genders. The persistence of the gender gap may suggest a role of inherent biological or anatomical differences between women and men, which have yet to be identified.
Limitations
The end point of bleeding/VC was not independently validated but was defined consistently and applied uniformly at each site by a dedicated quality assurance nurse. The NNE definition of bleeding/VC differs from the definitions used in other studies and limits the ability to directly compare results. Furthermore, there may still be unmeasured differences in women with and without bleeding/VC, which could confound the analysis. However, we can think of no good reason why there would be systematic differences in the data collection for women with and without bleeding/VC. These data do represent our regional experience and do question the generalized applicability to other populations. Our cardiovascular outcomes are limited to the index hospitalization, and the impact of bleeding/VC on longer term outcomes remains unanswered in our patient cohort. Finally, our analyses suggested a decreased risk of bleeding complications in women according to PCI pharmacology choices (bivalirudin as opposed to other agents), which is consistent with clinical trial results. 16 The data collection instrument does not discern indication for antithrombotic therapy or the duration of infusions, which may potentially confound the relationship between pharmacological agents and bleeding/vascular outcomes.
Conclusion
In this large regional multicenter registry, women undergoing PCI have had a significant decline in bleeding and VC rates during the last 6 years. Use of smaller sheaths, improved access techniques, safer antithrombotic therapy, and VCD in women represents modifiable variables, which may be protective. Despite the improvement in procedural safety, female gender continues to be associated with a Ͼ2-fold risk of bleeding and VC compared with men.
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CLINICAL PERSPECTIVE
Bleeding and vascular complications related to cardiac catheterization are associated with significant morbidity and mortality and are more prevalent among women undergoing the procedure. Over the last 2 decades, several proceduralrelated improvements have led to an overall decline in the incidence of cardiac catheterization-related bleeding and vascular complications; however, the impact of these improvements specifically in women has not been recently defined. Our contemporary report, from the Northern New England Percutaneous Coronary Intervention Registry, evaluating Ͼ13 600 women undergoing percutaneous coronary intervention from 2002 to 2007 shows a significant 50% improvement in rate of bleeding and vascular complications. Older women, women with renal failure, and those presenting with higher-risk acute coronary syndrome seem to be at the highest risk. Meanwhile, several procedural-related changes, such as routine use of fluoroscopy-guided access, smaller sheaths, safer pharmacotherapy, and closure devices, are associated with improved safety of the procedure. However, despite the overall reduction in rates and despite adjusting for baseline clinical and procedural differences, women continue to be at a higher inherent risk compared with men. This finding highlights the need for more focused research examining this difference.
